Multicentre registry analysis observes treatment satisfaction and quality of life differences in atrial fibrillation patients, highlighting the impact of anticoagulant choice.
: Oral anticoagulation (OAC) is pivotal in the clinical management of atrial fibrillation (AF) patients. Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) prevent thromboembolic events, but information about the quality of life (QoL) and patient satisfaction in relation with the anticoagulant treatment is limited.
No takes yet. Share an insight, caveat, or question.
Cabanas‐Grandío et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: